Posts by Mengxi Li

We provide access of investigtional fecal microbiota transplantation (FMT) preparation  to registered clinical partners who are treating recurrent C. difficile infections not responsive to standard therapies. We are working closely with the University of Minnesota (UMN) to prepare and submit a new IND that ensures consistency with recent changes to the guidance governing the use…

In December, OpenBiome held a live webinar to discuss a new FDA guidance governing the use of fecal microbiota transplantation (FMT) and the first FDA approval of a microbiome-based therapeutic for recurrent C. difficile (rCDI). OpenBiome, along with the University of Minnesota (UMN) Microbiota Therapeutics Program, will continue operating normally and remains committed to providing safe and continued…